Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IMMU-14 demonstrates evidence of activity

May 31, 1996

Approval to initiate NOVOMAb-G2 phase I studies granted by the FDA

May 31, 1996

Encouraging results of IDEC-C2B8 trial reported

May 31, 1996

Multikine trial commenced

May 31, 1996

Single-chain immunotoxin targeted to the CD40 antigen effect as cytotoxic agent

May 31, 1996

Daiwa's MGN-3 demonstrates immunotherapeutic activity

May 31, 1996

Role of DF3 in human carcinoma and potential therapeutics

May 24, 1996

Medarex presents MDX-210 phase I/II interim results

May 24, 1996

ImClone, E. Merck continue cancer vaccine collaboration

May 24, 1996

Vical, Corixa to collaborate on immunotherapeutic drugs for cancer

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 5, 2025.
CMS vows to put more emphasis on MA plans’ prior authorization
BioWorld MedTech
Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Associate degree: PTC’s hints of phase II HD efficacy studied
BioWorld
PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t...